Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC)

PHASE1RecruitingINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

January 9, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

June 30, 2028

Conditions
Unresectable Pancreatic Cancer
Interventions
DRUG

NRT6008 Injection + Systematic chemotherapy

"-Systematic chemotherapy The chemotherapy regimen is selected by the investigators at the consideration of participants' conditions, with either GN or (m)FOLFIRINOX.~GN: gemcitabine 1000 mg/m\^2 and nab-paclitaxel 125 mg/m\^2, every 21 days (3 weeks/cycle).~FOLFIRINOX: oxaliplatin 85 mg/m\^2, irinotecan 180 mg/m\^2, leucovorin 400 mg/m\^2 and fluorouracil 400 mg/m\^2 given as a bolus followed by 2400 mg/m\^2 given as a 46-hour continuous infusion, every 2 weeks (4 weeks/cycle).~mFOLFIRINOX: oxaliplatin 85 mg/m\^2, irinotecan 180 mg/m\^2, leucovorin 400 mg/m\^2, and fluorouracil 2400 mg/m\^2 given as a 46-hour continuous infusion, every 2 weeks (4 weeks/cycle).~-NRT6008 injection administration: NRT6008 injection is implanted into pancreatic tumor via endoscopic ultrasound (EUS)-guided fine-needle injection, at the instruction of the investigator. The dose of NRT6008 injection is determined by tumor volume and selected tumor average absorbed dose."

Trial Locations (6)

Unknown

RECRUITING

Henan Cancer Hospital, Zhengzhou

RECRUITING

Second Affiliated Hospital of Soochow University, Suzhou

RECRUITING

Shanghai Changhai Hospital, Shanghai

RECRUITING

Shanghai General Hospital, Shanghai

RECRUITING

Chongqing University Cancer Hospital, Chongqing

RECRUITING

Tianjin Medical University General Hospital, Tianjin

All Listed Sponsors
lead

Chengdu New Radiomedicine Technology Co. LTD.

INDUSTRY